Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–62 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo D5W Clear all

Conditions: Apnea of Prematurity, Intraventricular Hemorrhage, Brain Injury
Interventions: Caffeine citrate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 24 Weeks to 30 Weeks
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Subsyndromal Delirium
Interventions: Haloperidol decanoate, Placebo; Drug
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 84 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions: Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP); Drug
Lead sponsor: Richard Dart, MD, PhD; Other
Eligibility: 10 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Left Ventricular Insufficiency
Interventions: CD-NP, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transient Hypothyroxinemia of Prematurity (THOP)
Interventions: thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Hour to 24 Hours
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Pain, Post Operative Analgesia, Opioid Consumption, Postoperative
Interventions: Lidocaine HCl 0.8% in D5W, Dextrose 5% in water; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions: Intravenous Gemini, Intravenous placebo; Drug
Lead sponsor: Revelation Biosciences, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Chula Vista, California • La Mesa, California • San Antonio, Texas

Conditions: Reperfusion Injury
Interventions: Ascorbic Acid, 5 % Dextrose Water or Normal Saline; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 44
States / cities: Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more

Conditions: Healthy
Interventions: Oritavancin, Dextrose; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Pain
Interventions: TRV130, Morphine, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Pasadena, California • Houston, Texas

Conditions: IgA Nephropathy
Interventions: OMS721, Vehicle (D5W or saline); Biological · Other
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 34
States / cities: Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more

Search by objective public record fields.

MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Study of Thyroid Hormones in Prematures

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

A Study of TRV130 for the Treatment of Pain After Abdominoplasty

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy